News Sentiment

IRWD sentiment intelligence

Ironwood Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors Options RSS feed
Weighted score 53 Balanced news tone 65 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 4.23 Week of 31 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 65

directly relevant articles

Source quality 7

high-authority source matches

Trend context Trend inactive

+14.0% over one week, -2.3% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Ironwood Pharmaceuticals (IRWD) Is Up 14.2% After Raising 2026 Revenue Guidance – Has The Bull Case Changed?

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction 14.0% Price confirming higher
Trend fit Trend inactive -2.3% over four weeks
Fair value -15.6% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 49
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 65
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 17
TradingView 11
Market source 7
Seeking Alpha 6
Business Wire 5
simplywall.st 4
GuruFocus.com 1
MarketBeat 1

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 23
Guidance 5
Balance sheet 3
Deals and strategy 2
Analyst action 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 65
Associated Press Direct company coverage

Ironwood: Q2 Earnings Snapshot

Tone
Neutral 50/100
Event
Earnings
Published
06 Aug 2026 11:21
Source
Associated Press
Stock Titan Direct company coverage

BlackRock, Inc. (NASDAQ: IRWD) discloses 8.1% beneficial stake in Ironwood

BlackRock, Inc. has filed an amended Schedule 13G, disclosing an 8.1% beneficial ownership stake in Ironwood Pharmaceuticals Inc, totaling 13,373,568 shares of Class A stock. BlackRock exercises sole voting power over 13,195,313 shares and sole dispositive power over all 13,373,5

Tone
Neutral 50/100
Event
Deals and strategy
Published
28 Jul 2026 20:41
Source
Stock Titan
TradingView Direct company coverage

Return on assets % of Ironwood Pharmaceuticals, Inc. Class A – HAM:I76

The article provides financial data specifically focusing on the Return on Assets (%) for Ironwood Pharmaceuticals, Inc. Class A, traded under the symbol I76 on the Hamburg Stock Exchange. It indicates historical values and changes for this metric, noting that the market is curre

Tone
Neutral 50/100
Event
Market update
Published
27 Jul 2026 23:41
Source
TradingView
TradingView Direct company coverage

Total operating expenses of Ironwood Pharmaceuticals, Inc. Class A – HAM:I76

This article states the total operating expenses for Ironwood Pharmaceuticals, Inc. Class A, traded on the Hamburg Stock Exchange under the ticker I76. It indicates that the market is closed with no current trades. Further financial details would be available in a dedicated "Fina

Tone
Neutral 50/100
Event
Market update
Published
27 Jul 2026 17:40
Source
TradingView
TradingView Direct company coverage

Ironwood Pharmaceuticals, Inc. Class A Revenue Breakdown – BX:I76

Ironwood Pharmaceuticals, Inc. Class A (I76 BX Swiss) generated 234.78 million CHF last year, primarily from its Human Therapeutics segment. This represents a decrease from the previous year's 319.15 million CHF. The United States was the largest contributor to revenue, accountin

Tone
Neutral 50/100
Event
Earnings
Published
26 Jul 2026 11:10
Source
TradingView
TradingView Direct company coverage

Ironwood Pharmaceuticals, Inc. Class A Revenue Breakdown – SWB:I76

Ironwood Pharmaceuticals, Inc. (SWB:I76) generated €252.15 million in revenue last year, primarily from its Human Therapeutics segment. This marks a decrease from the previous year's €339.45 million, with the United States contributing the majority of the revenue.

Tone
Neutral 50/100
Event
Earnings
Published
25 Jul 2026 23:47
Source
TradingView
Stock Titan Direct company coverage

Ironwood Pharmaceuticals (IRWD) grants 137,036-share RSU new-hire award to CMO

Ironwood Pharmaceuticals Inc. (IRWD) has granted its SVP, CMO, and Head of Research & Drug Development, Jeffrey Silber, a new-hire restricted stock unit (RSU) award covering 137,036 shares of Class A Common Stock. This award vests 25% annually over four years and was issued at a

Tone
Neutral 50/100
Event
Market update
Published
22 Jul 2026 20:40
Source
Stock Titan
Investing.com Direct company coverage

Ronald Silver, PFO, sells $578k in Ironwood Pharma stock

Ronald Silver, Principal Financial Officer at Ironwood Pharmaceuticals (NASDAQ:IRWD), sold 127,890 shares of Class A Common Stock for over $578,000. This sale was part of a pre-planned trading strategy, and Mr. Silver still directly owns 313,680 shares. The transaction occurred a

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 07:40
Source
Investing.com
Investing.com Australia Direct company coverage

Ronald Silver, PFO, sells $578k in Ironwood Pharma stock By Investing.com

Ronald Silver, Principal Financial Officer of Ironwood Pharmaceuticals (NASDAQ:IRWD), sold 127,890 shares of Class A Common Stock for $578,062. This sale, executed via a Rule 10b5-1 trading plan, leaves him with 313,680 shares. The transaction follows recent strong financial resu

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 21:41
Source
Investing.com Australia
Stock Titan Direct company coverage

Ironwood (IRWD) finance chief sells 127,890 shares in 10b5-1 stock plan

Ronald Silver, Ironwood Pharmaceuticals' Principal Financial and Accounting Officer, sold 127,890 shares of Class A common stock at a weighted average price of $4.52 per share under a pre-arranged Rule 10b5-1 trading plan. Despite this sale, Silver retains a significant equity st

Tone
Negative 37/100
Event
Market update
Published
09 Jul 2026 20:40
Source
Stock Titan
TradingView Direct company coverage

ETFs Investing in Ironwood Pharmaceuticals, Inc. Class A Stocks

This article lists Exchange Traded Funds (ETFs) that hold Ironwood Pharmaceuticals, Inc. (IRWD) Class A stocks, sorted by market value. It provides key details for each ETF, such as issuer, management style, focus, expense ratio, assets under management (AUM), price, and performa

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 17:10
Source
TradingView
TradingView Direct company coverage

Ironwood Pharmaceuticals, Inc. Class A Actuals & Estimates (NASDAQ:IRWD)

This article provides an overview of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) stock performance, financial actuals, and analyst estimates. It highlights recent stock price movements, future price forecasts from analysts, historical highs and lows, and key financial metrics li

Tone
Positive 66/100
Event
Analyst action
Published
09 Jul 2026 04:10
Source
TradingView
TradingView Direct company coverage

Ironwood Pharmaceuticals, Inc. Class A Actuals & Estimates (SWB:I76)

This article provides an overview of Ironwood Pharmaceuticals, Inc. Class A (SWB:I76) including its financial actuals, analyst estimates, and key financial metrics. It covers information on stock performance, future earnings forecasts, past revenue, net income, and employee count

Tone
Positive 58/100
Event
Earnings
Published
30 Jun 2026 04:10
Source
TradingView
TradingView Direct company coverage

Ironwood Pharmaceuticals, Inc. Class A Actuals & Estimates (BX:I76)

This article provides financial actuals and estimates for Ironwood Pharmaceuticals, Inc. Class A (BX:I76), covering income statements, balance sheets, and cash flow data. It includes analyst forecasts, earnings reports, revenue figures, and other financial metrics. The company's

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 05:39
Source
TradingView
TradingView Direct company coverage

I76 Forecast — Price Target — Prediction for 2027

This article provides a forecast for Ironwood Pharmaceuticals, Inc. Class A (I76), including analyst price targets and predictions for 2027. It details earnings, revenue, and net income figures, and answers frequently asked questions about the company's stock, historical prices,

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 23:39
Source
TradingView
TradingView Direct company coverage

Ironwood Pharmaceuticals, Inc. Class A Actuals & Estimates (MUN:I76)

This article provides actuals and estimates for Ironwood Pharmaceuticals, Inc. Class A (MUN:I76), covering financial data, analyst forecasts, and company details. It includes information on earnings, revenue, net income, and dividend policy, as well as an overview of its stock pe

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 20:10
Source
TradingView
Stock Titan Direct company coverage

Director Catherine Moukheibir receives 63,481 Ironwood (IRWD) restricted shares

Ironwood Pharmaceuticals director Catherine Moukheibir has received an equity award of 63,481 shares of Class A common stock, granted as restricted stock with no cash cost. These shares will vest in full on the day before the next annual stockholders' meeting, requiring her conti

Tone
Neutral 50/100
Event
Balance sheet
Published
21 Jun 2026 03:10
Source
Stock Titan